Short term ex vivo 3D culture expansion of patient-derived tumor material in a 3D environment and subsequent exposure to cancer therapeutics enables clinically-relevant functional in vitro testing of pre-clinical compounds.
Using a high throughput 384 well plate format, over 100 tumoroids per well can be exposed to multiple drug treatments, dose ranges and drug combinations in parallel. Tumoroids are fixed and stained with cellular markers. 3D image stack acquisition is followed by high content multi-parametric analysis using the OMinerTM platform to profile drug responses and quantify tumor spheroid volume, apoptosis and tumor invasion. This compound testing platform allows drug testing in well characterized PDX tumor material with the option of in vivo follow-up in the same PDX model from which the tumor cells were derived.